mutagrip sospensione iniettabile
sanofi-aventis (suisse) sa - haemagglutininum influenzae di tipo a (h1n1) (virus souche un/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275), haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b), haemagglutininum influenzae b (virus souche b/brisbane/60/2008) - sospensione iniettabile - haemagglutininum influenzae di tipo a (h1n1) (virus souche un/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b) 15 µg, haemagglutininum influenzae b (virus souche b/brisbane/60/2008) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, il resto: formaldehydum max. 100 µg, octoxinolum-9 max. 500 µg, ovalbuminum max. 0,05 µg sintetiche, no, neomycinum nulla, l'acqua ad iniectabilia q.s. la sospensione 0,5 ml. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - vaccini
efluelda 0.7 ml suspension injectable en seringue préremplie
sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015), haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186 derived from a/singapore/infimh-16-0019/2016 ), haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) - suspension injectable en seringue préremplie - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015) 60 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186 derived from a/singapore/infimh-16-0019/2016 ) 60 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage) (wild type)) 60 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.7 ml corresp. natrium 2.72 mg. - immunisation active contre l'influenza, dès 65 ans - vaccini
supemtek 0.5 ml solution injectable dans une seringue pré-remplie
sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (rha) (virus souche a/michigan/45/2015)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015), haemagglutininum influenzae a (h3n2) (rha) (virus souche a/singapore/infimh-16-0019/2016)-like: reassortant virus ivr-186 derived form a/singapore/infimh-16-0019/2016), haemagglutininum influenzae b (rha) (virus souche b/phuket/3073/2013-like: reassortant virus b/phuket/3073/2013 (yamagata lineage)) - solution injectable dans une seringue pré-remplie - haemagglutininum influenzae a (h1n1) (adnr) (virus souche a/michigan/45/2015)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015) 45 µg, haemagglutininum influenzae a (h3n2) (adnr) (virus souche a/singapore/infimh-16-0019/2016)-like: reassortant virus ivr-186 derived form a/singapore/infimh-16-0019/2016) 45 µg, haemagglutininum influenzae b (adnr) (virus souche b/phuket/3073/2013-like: reassortant virus b/phuket/3073/2013 (yamagata lineage)) 45 µg, haemagglutininum influenzae b (adnr) (virus souche b/colorado/6/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 45 µg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas dodecahydricus, natrii chloridum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml corresp. natrium 1.84 mg, residui: octoxinolum-9. - immunisation active contre l'influenza, dès 18 ans - vaccini
vaxigriptetra sospensione iniettabile in siringa pre-riempita
sanofi-aventis (suisse) sa - haemagglutininum influenzae di tipo a (h1n1) (ceppo del virus a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275), haemagglutininum influenzae a (h3n2) (ceppo del virus a/singapore/infimh-16-0019/2016 (h3n2)-come: reassortant virus ivr-186), haemagglutininum influenzae b (virus del ceppo b/colorado/06/2017-come: reassortant virus nymc bx-69a derivata da b/veneto/15/2016 (victoria lignaggio)) - sospensione iniettabile in siringa pre-riempita - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186) 15 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: reassortant virus wild type derived from b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - impfstoffe
mutagrip sospensione iniettabile
sanofi-aventis (suisse) sa - haemagglutininum influenzae di tipo a (h1n1) (ceppo del virus a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275), haemagglutininum influenzae a (h3n2) (ceppo del virus a/singapore/infimh-16-0019/2016 (h3n2)-come: reassortant virus ivr-186), haemagglutininum influenzae b (virus del ceppo b/colorado/06/2017-come: reassortant virus nymc bx-69a derivata da b/veneto/15/2016) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186) 15 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, residui: formaldehydum max. 30 µg, octoxinolum-9 max. 200 µg, neomycinum max. 7.5 pg, ovalbuminum max. 50 ng, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - impfstoffe
influvac sospensione iniettabile
bgp products gmbh - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b), haemagglutininum influenzae b (virus-stamm b/brisbane/60/2008) - sospensione iniettabile - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b) 15 µg, haemagglutininum influenzae b (virus-stamm b/brisbane/60/2008) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcio chloridum dihydricum, magnesio chloridum hexahydricum, il resto: ovalbuminum max. 0,1 µg, formaldehydum e cetrimidum e polysorbatum 80 e gentamicinum nulla, l'acqua ad iniectabilia q.s. la sospensione 0,5 ml. - immunizzazione attiva contro l'influenza, che abbiano compiuto il 6. mese di vita - vaccini
efluelda 0.7 ml suspension injectable en seringue préremplie
sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus san-010 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: derived from b/michigan/01/2021 (victoria lineage)(wild type)) - suspension injectable en seringue préremplie - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 60 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus san-010 derived from a/darwin/9/2021) 60 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: derived from b/michigan/01/2021 (victoria lineage)(wild type)) 60 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage) (wild type)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.7 ml corresp. natrium 2.72 mg. - immunisation active contre l'influenza, dès 65 ans - vaccini
fluarix tetra 15 µg / 0.5 ml sospensione iniettabile
glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021), haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021) 15 µg, haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013-like: b/phuket/3073/2013 wild type (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini
fluarix tetra 15 µg / 0.5 ml sospensione iniettabile
glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/tasmania/503/2020), haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/tasmania/503/2020) 15 µg, haemagglutininum influenzae b (virus stamm b/washington/02/2019-like: reassortant virus b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini
vaxigriptetra sospensione iniettabile in siringa pre-riempita
sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/cambodia/e0826360/2020), haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) - sospensione iniettabile in siringa pre-riempita - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/cambodia/e0826360/2020) 15 µg, haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - vaccini